Skip to main content
GoodMoatv1.3
Sign in
VCEL logo

VCEL

CompareEarnings: May 31, 2026

Vericel Corp

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns.

Did you know?

Trading 29% above its estimated fair value of $25.84.

Current Price

$36.49

+2.59%

GoodMoat Value

$25.84

29.2% overvalued
Profile
Valuation (TTM)
Market Cap$1.85B
P/E111.72
EV—
P/B5.20
Shares Out50.57M
P/Sales6.68
Revenue$276.26M
EV/EBITDA51.69

Vericel Corp (VCEL) Company Profile

VCEL Company Information

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets.

The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives.

Vericel markets three products in the United States.

MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.

Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.

Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

Massachusetts, USA

VCEL Key Officers

Key officers data coming soon

VCEL Company Profile

Vericel Corp (VCEL) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in Massachusetts, USA.

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns.

Market cap is $1.85B. There are 50.6M shares outstanding.

See the full Vericel Corp profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if VCEL is a good investment.